Investigators conducted a prospective analysis in patients with HIV to assess the rate of switching from TDF-based to TAF-based or dual therapy regimens and to assess the impact of switching on eGFR.
A major concern in people with HIV includes accelerated atherosclerosis, underlined by increased rates of coronary artery disease. Researchers investigated the longitudinal progression of atherosclerosis in persons with HIV vs without HIV in the Swiss population.
Researchers assessed the risk of diabetes mellitus, weight gain, and their relationships with integrase inhibitor-based initial antiretroviral therapy among persons with HIV in the United States and Canada.
Italian investigators conducted a prospective, multicenter study to assess the safety and effectiveness of glecaprevir/pibrentasvir in chronic hepatitis C patients and their subpopulations.
Researchers conducted a retrospective cohort study to analyze national trends in drug payments and other associated costs of HIV PrEP treatment.
Patients with persistent ALT elevation despite controlled HBV should undergo evaluation for metabolic risk and fatty liver disease.
Researchers studied 61 HIV-infected individuals who switched from efavirenz- to integrase strand transfer inhibitor (INSTI)-based therapies.
Researchers evaluated the results of multiple phase 2 and phase 3 clinical trials and found that drug resistance to darunavir, an HIV protease inhibitor, is rare.
A team of investigators conducted an individual patient data meta-analysis to evaluate how treatment for tuberculosis and antiretroviral therapy affect the risk of mortality in patients with HIV and multidrug-resistant tuberculosis.
In post-hoc analyses, researchers analyzed alcohol use data and whole-blood samples from 359 participants in the New Orleans Alcohol Use in HIV study to explore the association between intestinal leak, dysbiosis, and T cells.
Previously, Dovato was only approved for treatment-naïve adults.
A novel tenofovir urine immunoassay demonstrated predictive utility and may adequately determine PrEP adherence.
A first clinical experience with brodalumab in an HIV-positive patient proves successful and may imply the utility of brodalumab in this patient group.
By providing bundled HIV and HCV testing, substance use disorder treatment programs may create increased awareness of infection status among people with substance abuse disorders.
Despite treatment with antiretroviral therapies, people with HIV may be more likely to experience severe manifestations of COVID-19.
A cross-sectional study was performed to assess whether age, body mass index, and/or components of antiretroviral therapy contributed to persistence of HIV viremia.
A team of investigators conducted a randomized trial comparing test-guided management of tuberculosis with systematic empirical treatment for adults with HIV infection.
A working group comprising members with expertise in virology, molecular epidemiology, public health, bioethics, community engagement, social work, community-based HIV research, and law was assembled to address ethical challenges in US-based HIV phylogenetic research.
A small molecule that disrupts the functions of the HIV capsid protein, GS-6207, demonstrates a reduction in plasma viral load and shows sustained plasma exposure.
Efforts to reduce new HIV infections in children worldwide are faltering.